A Potential Breakthrough in Breast Cancer Treatment?
In an exciting development, researchers have uncovered a new role for an old drug, dexamethasone, in the fight against therapy-resistant breast cancer metastases. This discovery could offer hope to patients facing this challenging form of cancer.
Dexamethasone, a synthetic signaling substance, has long been used to alleviate the side effects of chemotherapy. However, scientists at the University of Basel have now found that it possesses an additional, powerful ability.
The Battle Against Therapy-Resistant Breast Cancer
Breast cancer, particularly the "estrogen receptor-positive" (ER+) subtype, is often treated with anti-hormonal therapy. This therapy targets the hyperactive estrogen receptor, which drives abnormal cell division. While effective, some tumors develop resistance, leading to the formation of metastases that no longer respond to hormone therapy.
Dexamethasone's Secret Weapon
In a study published in EMBO Molecular Medicine, a research team led by Professor Mohamed Bentires-Alj reported that dexamethasone can combat these therapy-resistant metastases. In trials with mice, dexamethasone reduced liver metastases and extended the animals' survival. The drug achieves this by activating the glucocorticoid receptor, which suppresses the production of the estrogen receptor, essentially removing the main driver of tumor growth.
Dr. Madhuri Manivannan, the lead author, commented, "As a result, the cancer cells lose the main driver of tumor growth."
Confirming the Findings
To further validate their findings, the researchers used patient-derived tumor tissue, known as organoids, grown in the laboratory. Here too, they observed a decrease in the estrogen receptor with the addition of dexamethasone.
Dr Charly Jehanno, who led the research project, said, "Dexamethasone could potentially directly support certain breast cancer therapies, not just as a side treatment for nausea and inflammation."
A New Lease of Life for an Established Drug
If the metastasis-inhibiting effect is confirmed in clinical trials, dexamethasone could be repurposed for this new application. This would be a significant development, offering a new treatment option for patients with therapy-resistant breast cancer.
But Here's Where It Gets Controversial...
Interestingly, dexamethasone's impact on breast cancer varies depending on the type. In 2019, Professor Bentires-Alj's team reported that dexamethasone promotes metastases in triple-negative breast cancer, highlighting the complex nature of this disease and the need for personalized treatment approaches.
The Bottom Line
This research offers a glimmer of hope for patients with therapy-resistant breast cancer. However, more studies are needed to confirm these findings and determine the potential of dexamethasone in this context. It's an exciting development, but we must remember that cancer is a complex disease, and further research is always needed.
What are your thoughts on this potential breakthrough? Do you think this could be a game-changer for breast cancer treatment? Let us know in the comments!
